This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007; 40: 443–450.
Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant 2009; 15: 118–125.
RodrÃguez J, Conde E, Gutiérrez A, Arranz R, León A, MarÃn J et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18: 652–657.
Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG . Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008; 14: 741–747.
Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 2010; 45: 311–316.
Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 106–113.
d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093–3099.
Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176.
Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008; 26: 2264–2271.
Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006; 108: 382–389.
Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520–526.
Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S . Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012; 47: 65–72.
Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 3951–3958.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2007.
Vose J, Armitage J, Weisenburger D . International T-Cell Lymphoma Project: international peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124–4130.
Acknowledgements
We would like to thank pathologists Dr Hironori Haga and Dr Yoon Kyung Jeon for attending the consensus conference. We also thank the JSCT Office for outstanding data management. Further, we thank Dr Yoichi Takaue, Dr Kensei Tobinai, Dr Takashi Watanabe and Dr Shigeo Fuji for the discussions. This work was supported by a grant from the Regional Medicine Research Foundation (Utsunomiya, Japan).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Kim, SW., Yoon, SS., Suzuki, R. et al. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia 27, 1394–1397 (2013). https://doi.org/10.1038/leu.2012.321
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.321
This article is cited by
-
Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL
Leukemia (2022)
-
Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma
Clinical and Experimental Medicine (2022)
-
Management of Peripheral T-cell Lymphomas and the Role of Transplant
Current Oncology Reports (2022)
-
Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma
Bone Marrow Transplantation (2021)
-
Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome
Bone Marrow Transplantation (2021)